Mon, February 28, 2011
Sun, February 27, 2011
[ Sun, Feb 27th 2011 ] - Market Wire
Sukari Gold Exports
[ Sun, Feb 27th 2011 ] - Market Wire
Athena Field Development
Sat, February 26, 2011
Fri, February 25, 2011
Thu, February 24, 2011
[ Thu, Feb 24th 2011 ] - Market Wire
CIBC declares dividends
Wed, February 23, 2011
Tue, February 22, 2011
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
[ Fri, Feb 18th 2011 ] - Market Wire
Company Update
Thu, February 17, 2011
[ Thu, Feb 17th 2011 ] - Market Wire
Vascular(TM)
Wed, February 16, 2011

Granting of nematodes patent


//business-finance.news-articles.net/content/2011/02/22/granting-of-nematodes-patent.html
Published in Business and Finance on Tuesday, February 22nd 2011 at 23:20 GMT by Market Wire   Print publication without navigation


 GB0001646941/GBP/PLUS-exn 23 February 2011 EDEN RESEARCH PLC ("Eden" or the "Company") Granting of nematodes patent Eden Research plc, a leading UK agrochemical development company, is pleased to announce the first granting of its 'nematodes' patent in Australia. The patent, which is for the use of Eden's platform encapsulation technology with terpenes as a nematicide, is also in an advanced state of registration in a number of other countries. The patented encapsulation system itself has already been granted in a number of territories. Nematodes are microscopic, soil-dwelling worms measuring approximately 0.1-5 mm in length. Nematode populations can cause considerable damage to a wide range of high-value vegetable crops and horticultural species. Eden has already licensed its nematicide product in South America to Stockton Agrimor AG and granted an option for the product to Certis Europe BV to enter into an exclusive licence for Europe, Asia, Africa, the Middle East and Oceania. Clive Newitt, Managing Director of Eden Research plc said, "The nematode market has been as high as $1.1bn worldwide but due to regulatory withdrawal of many previous products, such as Temik® (aldicarb), there is a vacuum waiting to be filled by naturally derived, effective, cost competitive products such as Eden's. The granting of this patent is important not only for the nematode licences that we have signed to date, but, also for reinforcing the value of the company's intellectual property." The Directors of Eden are responsible for the contents of this announcement. Enquiries: Eden Research plc 01993 862761 Clive Newitt, Managing Director St Helens Capital Partners LLP 020 7368 6959 Mark Anwyl Notes: Eden's strategy is focused on the development and commercialisation of its terpene-based encapsulation technology for agricultural and non-agricultural uses through appropriate regional or global partnerships. Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries. Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides the unique, natural solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals. For more information, please visit www.edenresearch.com 


Publication Contributing Sources